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specific aims of the thesis. It includes a brief account of the usefulness of survival analysis 
using population-based data in cancer control and in evaluating performance of cancer 
services both temporally and spatially.  
 
The second contains a review of the literature on geographical and temporal variation in 
survival using population-based cancer registry data, which sets the scene for the following 
chapters. I also critically evaluated the limitations and strengths of the studies in this field in 
relation to the following chapters. 
 
The third chapter is our paper “Yu XQ, O’Connell DL, Gibberd RW, Smith DP, Dickman 
PW, Armstrong BK. Estimating regional variation in cancer survival: a tool for improving 
cancer care. Cancer Causes Control 2004; 15:611-8”. The chapter mainly describes the 
methods for estimating regional variation in cancer survival and use of these estimates to 
identify cancers with the greatest potential for improving care outcomes with prioritisation of 
actions targeted against such cancers. 
 
The fourth chapter is our paper “Yu XQ, O’Connell DL, Gibberd RW, Armstrong BK. A 
population-based study from New South Wales, Australia 1996-2001: area variation in 
survival from colorectal cancer. Eur J Cancer 2005; 41:2715-21”. The paper describes an 
application of the methods described in the third chapter to colorectal cancer, gives a more 
complete analysis of regional variation in colorectal cancer survival and explores the possible 
reasons for the survival difference among regions in New South Wales, Australia.  
 
The fifth chapter is our paper “Yu XQ, O’Connell DL, Gibberd RW, Coates AS, Armstrong 
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New South Wales Australia. Int J Cancer 2006; 119:894-900”. In this paper, I examined time 
trends in survival for patients diagnosed with any of 28 cancers between 1980 and 1996 in 
NSW, with adjustment for disease spread at diagnosis and cancer histology.  
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assessed the impact of measurement error on estimates of regional variation in stage-specific 
survival, an extension of Chapter 4.  
 
The last chapter provides a broad discussion and conclusions drawn from the work described 
in the thesis. I broadly discuss the usefulness of survival analysis based on cancer registry 
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identifying cancer types or geographical areas with extremely poor performance requiring 
prompt action to improve outcomes of patient care.  
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Abstract 
Over the past decade, population-based cancer registry data have been used increasingly 
worldwide to evaluate and improve the quality of cancer care. The utility of the conclusions 
from such studies relies heavily on the data quality and the methods used to analyse the data. 
Interpretation of comparative survival from such data, examining either temporal trends or 
geographical differences, is generally not easy. The observed differences could be due to 
methodological and statistical approaches or to real effects. For example, geographical 
differences in cancer survival could be due to a number of real factors, including access to 
primary health care, the availability of diagnostic and treatment facilities and the treatment 
actually given, or to artefact, such as lead-time bias, stage migration, sampling error or 
measurement error. Likewise, a temporal increase in survival could be the result of earlier 
diagnosis and improved treatment of cancer; it could also be due to artefact after the 
introduction of screening programs (adding lead time), changes in the definition of cancer, 
stage migration or several of these factors, producing both real and artefactual trends. In this 
thesis, I report methods that I modified and applied, some technical issues in the use of such 
data, and an analysis of data from the State of New South Wales (NSW), Australia, 
illustrating their use in evaluating and potentially improving the quality of cancer care, 
showing how data quality might affect the conclusions of such analyses. 
This thesis describes studies of comparative survival based on population-based cancer 
registry data, with three published papers and one accepted manuscript (subject to minor 
revision). 
In the first paper, I describe a modified method for estimating spatial variation in cancer 
survival using empirical Bayes methods (which was published in Cancer Causes and Control 
2004). I demonstrate in this paper that the empirical Bayes method is preferable to standard 
approaches and show how it can be used to identify cancer types where a focus on reducing 
area differentials in survival might lead to important gains in survival. 
In the second paper (published in the European Journal of Cancer 2005), I apply this method 
to a more complete analysis of spatial variation in survival from colorectal cancer in NSW 
and show that estimates of spatial variation in colorectal cancer can help to identify subgroups 
of patients for whom better application of treatment guidelines could improve outcome. I also 
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show how estimates of the numbers of lives that could be extended might assist in setting 
priorities for treatment improvement. 
In the third paper, I examine time trends in survival from 28 cancers in NSW between 1980 
and 1996 (published in the International Journal of Cancer 2006) and conclude that for many 
cancers, falls in excess deaths in NSW from 1980 to 1996 are unlikely to be attributable to 
earlier diagnosis or stage migration; thus, advances in cancer treatment have probably 
contributed to them. 
In the accepted manuscript, I described an extension of the work reported in the second paper, 
investigating the accuracy of staging information recorded in the registry database and 
assessing the impact of error in its measurement on estimates of spatial variation in survival 
from colorectal cancer. The results indicate that misclassified registry stage can have an 
important impact on estimates of spatial variation in stage-specific survival from colorectal 
cancer. Thus, if cancer registry data are to be used effectively in evaluating and improving 
cancer care, the quality of stage data might have to be improved. 
Taken together, the four papers show that creative, informed use of population-based cancer 
registry data, with appropriate statistical methods and acknowledgement of the limitations of 
the data, can be a valuable tool for evaluating and possibly improving cancer care. Use of 
these findings to stimulate evaluation of the quality of cancer care should enhance the value 
of the investment in cancer registries. They should also stimulate improvement in the quality 
of cancer registry data, particularly that on stage at diagnosis. The methods developed in this 
thesis may also be used to improve estimation of geographical variation in other count-based 
health measures when the available data are sparse. 
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Chapter 1 Introduction  
 
About this chapter 
This chapter provides the background for my thesis. First, I describe the aims of this 
thesis. In the following ‘Background’ section, I provide a brief overview of the use of 
population-based cancer registry data in evaluating the quality of cancer care in other 
countries to provide the context for the following chapters. In this section, I discuss 
the strengths and limitations of population-based cancer registry data and survival 
analysis and their usefulness in evaluating and potentially improving the quality of 
cancer care. In addition, I describe the research problems investigated in the following 
chapters and methods for overcoming issues in the use of population-based data in 
evaluating the quality of cancer care and the justification for doing this research. 
 
Thesis aims 
My primary aim in conducting the research contained in this thesis is to examine the 
usefulness of population-based cancer registry data in evaluating and potentially 
improving the quality of cancer care. In addition, this thesis has two secondary aims. 
The first is to explore and apply appropriate statistical methods to overcome the 
limitations of such data in measuring health service performance, such as sampling 
errors, confounding factors, lead-time bias, and measurement errors. The second is to 
assess the impact of registry data quality on estimates of geographical or temporal 
differences in survival. 
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Background – Survival is an important measure of patient care 
Although the efficacy of cancer therapy is best evaluated by studying patient 
outcomes in randomised clinical trials, the patients in most clinical trials have 
generally not been followed long enough for long-term survival to be evaluated. 
Studies using population-based cancer registries allow for much longer follow-up. 
Moreover, in contrast to a clinical trial, in which patients might be excluded on the 
basis of disease stage at diagnosis, age or co-morbid illness, studies using population-
based registry data represent the experience of a general population of people with 
cancer. They thus represent the full spectrum of care that patients receive or fail to 
receive during and after diagnosis, not care from particular hospitals or cancer therapy 
centres. More importantly, the results of clinical trials might differ from actual 
treatment outcomes in everyday practice.1 Population-based data can provide insights 
into the practical effectiveness of treatments that cannot be obtained from trials. 
However, there are some disadvantages in using population-based cancer registry data 
for measuring health service performance since cancer registry data are primarily used 
to estimate cancer incidence rates. Most cancer registries do not collect treatment and 
co-morbidity information for the patients, and cancer stage at diagnosis is also often 
not collected. Even for registries that do collect this information, the data quality is 
not as good as in clinical trials: some data may not be accurately recorded or may be 
missing altogether. Despite these limitations, I argue that studies using population-
based registry data are worth doing because of their representativeness and 
generalisability. 
 
During the past decade, population-based cancer registry data have been used 
worldwide to assess progress in cancer management and to compare cancer outcomes 
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between population subgroups and geographical areas. Such studies generally focus 
on broad patterns of cancer care, with a special interest in quality and outcome of care 
and geographical, ethnic, social and temporal variation. There is ongoing interest in 
understanding the causes of such variation and in developing effective interventions 
to reduce the frequency of inappropriate or poor-quality care and, in some instances, 
to reduce inequality in care or outcome between population sub-groups. 
 
Cancer registries are recognised as being among the best of all public health 
surveillance systems with regard to completeness, accuracy, data availability and 
timeliness of reporting. The data are a ready source for addressing some questions 
related to the quality of cancer care, which is currently a high priority for cancer-
related health services research. Because of their legal mandate, cancer registries are 
uniquely situated to identify a population-based sample of incident cancer patients 
and are the best source for measuring the quality of cancer care in whole populations.2 
In the past, much of the information collected was used to study cancer epidemiology 
and the causes of cancer; but was underutilised to measure the performance of cancer 
care.  
 
Survival can be used to quantify the effectiveness of early detection and treatment at 
the population level and is thus an important component in monitoring cancer control. 
Registry data often include the stage, histopathology, vital status and some patient 
descriptors. Patient survival, therefore, can be used as the basis for quality measures 
particularly if there is the capacity for risk adjustment. The aims of such studies 
include: monitoring the global effect of diagnostic and treatment improvements, 
establishing priorities for healthcare investment and research, estimating the potential 
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for further improvement, planning clinical trials, and carrying out studies on the 
equity of the health service.  
 
Relative survival is the most widely used method of survival analysis based on 
population-based cancer registry data. It is usually defined as a measure of excess 
mortality due to a diagnosis of cancer; that is, it is “corrected” for background 
mortality.3 It compares the survival of cancer patients to that of the general population 
in which they belong. The advantage of relative survival is that no information on 
cause of death is required; this information is either unavailable or inaccurate for 
many cancer registries.4;5 Even if cancer registries routinely collect cause of death 
information, it is difficult to separate causes “entirely due to cancer” from causes 
“completely unrelated to cancer” and the “shades of grey” between them. Thus, 
relative survival provides a more objective and possibly more accurate means of 
removing the effect of mortality from other causes.6  
 
Although there has been increased use of population-based cancer registry data for 
cancer-related health services research, since the work for this thesis began, only a 
few studies from Europe have been published that systematically address methods for 
overcoming the limitations of such data, and none have been published in Australia. 
To the best of my knowledge, there was no published study in the literature that both 
quantified the measurement error in disease stage at diagnosis, a critical factor in 
survival, and examined its impact on temporal or geographical area variation in 
survival. There was, therefore, a need to address these issues using data from 
population-based cancer registries, especially paying attention to the quality of the 
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data and to reduce the measurement error on estimated geographical variation or 
temporal trends. 
 
In this thesis, I report on the methods modified to address the above issues and 
explore the technical issues involved. I illustrate these methods for evaluating and 
potentially improving the quality of cancer care, and also show how data quality can 
affect the conclusions drawn from such analyses. Chapter 3 is primarily about dealing 
with sampling errors by using the empirical Bayes method, and the use of stage 
adjustment is aimed at addressing a confounding factor and lead-time bias. In Chapter 
4, I provide more detailed analyses to address these issues and interpretation of the 
NSW Cancer Registry data. Chapter 5 provides comprehensive analyses of trends in 
survival by taking lead-time bias and stage migration into account. Stage migration is 
dealt with by careful interpretation of the results of survival over time, trends in 
incidence and changes in stage distribution over time. In Chapter 6, I address an 
aspect of measurement error of disease stage at diagnosis recorded on the registry 
database as well as other issues dealt with in Chapters 3 and 4. In Chapter 7, I bring 
all the findings from this thesis together and discuss what the thesis as a whole 
contributes to new knowledge about the usefulness of survival analysis based on 
cancer registry data. 
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Chapter 2 Literature Review 
 
About this chapter 
In this chapter I have provided a detailed review of previous studies of survival from 
cancer using population-based cancer registry data. The studies included in this 
review are studies of geographical variation in survival and trends in survival 
published since 1996. I chose to limit the review to the most recent studies because 
they are more relevant to this thesis. 
 
Survival variation between geographical areas 
Studies of geographical variation in cancer survival since 1996 have examined 
numerous sites, including breast,7-20 colon and rectum,7-12;21-28 lung,7-12;16;22;29-31 
prostate,7-12;16;22;32 melanoma,8;12;16;22;23 stomach,7;10;12;16;22;23;33 cervix,8;12;16;22 
ovary,7;10;12;16 and non-Hodgkin lymphoma (NHL),8;12;16 and in many countries. Some 
such studies focused on a single cancer type with an in-depth analysis while others 
included selected, frequently occurring cancers, providing an overview of cancer 
survival across different cancer types. The relevant studies included in this review are 
summarised in Table 1.  
 
Among those studies including multiple types of cancers, EUROCARE is the first 
large-scale international project to compare cancer survival across a number of 
different countries, using data from population-based cancer registries.34-37 The 
EUROCARE database included 4 million cancer cases from 65 cancer registries in 20 
European countries. The main results of its analyses revealed wide international 
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differences in survival among cancer patients diagnosed in 12 European countries 
between 1978 and 1985,37 and among patients diagnosed in 17 European countries 
between 1985 and 1989.38 Similar kinds of studies comparing survival from multiple 
cancer types between several geographical areas have been conducted in Australia,8 
Canada,9 Nordic countries,22;23 Scotland7 and the USA.10 Generally these studies 
included the more frequently occurring cancers, such as breast, colon and rectum, 
lung and prostate cancers and melanoma.  
 
For those studies focusing on a single cancer type, the most studied cancer types were 
breast and colorectal cancer because these two cancers affect large numbers of people, 
and have an important impact on the population. Moreover, due to the availability of 
methods for early diagnosis and effective treatments if detected early, geographical 
variation in survival is likely to exist. The data from the EUROCARE study 
highlighted wide differences in survival from breast cancer between European 
countries.14;15 These studies are based on large numbers of cases (119,139 and 
145,000 respectively) across 12-17 countries, where the cancer registries supplied 
uniform data, thus the results are representative of large geographical areas in Europe. 
Similar results for breast cancer were also found in England, Scotland and the USA. 
Using the English National Cancer Registry data, Mullee et al39 reported that for 
78,904 women diagnosed with breast cancer between 1992 and 1994, large and 
significant variation was found in 5-year relative survival (from 66% to 85%) among 
99 health authorities (p<0.001). Twelves et al20 analysed data on 1617 breast cancer 
patients diagnosed in 1987 in Scotland and found that Health Board was an important 
determinant of patient survival at both 5 years (p=0.04) and 10 years (p=0.004) after 
adjusting for age, clinical stage, oestrogen receptor status, pathological node status 
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and pathological tumour size. Using the Surveillance, Epidemiology, and End Results 
(SEER) registry data, Goodwin et al13 found significant variation in survival across 
the 66 health service areas (p<0.0001) in the older (aged 65 and older) US population 
of women diagnosed with breast cancer in 1985-1991.  
 
All these studies on breast cancer survival, among different countries with large study 
populations, suggest that the effect of place of residence is probably real. What are the 
causes of such variation? There are a variety of possible explanations but two are 
most likely: stage at diagnosis and efficacy of treatment. To separate these two and to 
analyse their effect on survival between geographical areas, reliable data on disease 
stage and treatment are required. However, the variation in survival in the Scottish 
study remained significant after taking account of differences in stage between health 
boards, which led them to believe that the most likely explanation was differences in 
local or adjuvant systemic treatment between Health Boards.20 The EUROCARE high 
resolution study is an extension of the EUROCARE study with additional collection 
of information on disease stage, staging procedures, and treatments for a 
representative sample of cases from 17 European cancer registries. Using these data 
Sant et al17 concluded that stage at diagnosis is a key explanation of differences in 
breast cancer survival across Europe. In this study, the authors used multiple 
regression models to assess the impact of disease stage on 5-year relative survival for 
breast cancer in 1990-92 between 17 cancer registries in 6 European countries. The 
first model, only adjusting for age, did not substantially change the relative survival 
pattern. After additional adjustment for stage and surgery, the relative excess risk 
(RER) of death in most regions moved towards 1, indicating that stage was a key 
determinant of regional variation in survival. A further movement of the RER towards 
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1 occurred after adjustment for the number of lymph nodes examined. However, the 
fact that the RER remained higher in 3 regions suggests that the management of breast 
cancer patients is not optimal in those areas.17 Applying the known effective treatment 
to all sub-groups in the population would, therefore, reduce the geographical variation 
in breast survival, as suggested by Goodwin et al.13 
 
Geographical variation in survival for colorectal cancer is also well studied. Studying 
variation in survival among 5147 colorectal cancer cases diagnosed in 1991-95 in the 
Wessex region, south England, Kim et al26 concluded that district of treatment showed 
a highly significant relationship to survival after adjusting for stage and surgery type. 
Gatta et al24 reported that 5-year relative survival from colorectal cancer differed 
significantly across European countries, ranging from 23% to 59% for colon cancer 
and 22% to 53% for rectal cancer. Using the data from the EUROCARE high 
resolution study, Gatta et al25 found that survival from colorectal cancer varied 
markedly between European countries and there was a twofold range in the risk of 
death from this cancer even after adjustment for surgery and disease stage at 
diagnosis. Differences in survival from cancers of the colon and rectum are especially 
marked in the first 6 months after treatment, suggesting that there are effects from 
stage at diagnosis and/or access to optimal care.25 However, Prior et al27 and 
Woodman et al40 disagreed with the view and concluded that the observed survival 
differentials may not be due to differences in the quality of care but may reflect 
misdiagnosis or a failure of some European registries to register all patients with 
advanced disease. In a study comparing survival between European and US patients 
diagnosed with colorectal cancer in 1990-91 using data from 10 European and 9 
SEER registries, Ciccolallo et al21 concluded that US-Europe survival differences in 
  10 
 
colorectal cancer were large but seem to be mostly attributable to differences in stage 
at diagnosis. After adjusting for age, sex, site, stage, resection and number of lymph 
nodes examined, the relative excess risks of death due to colorectal cancer were 
similar in 5 of the 10 European registries when compared to that of the US, cases in 
one registry had a lower relative excess risk than US patients.21 
 
Other studies of geographical variation in survival for single cancers were for lung, 
head and neck, prostate and stomach cancers. This group of cancers are studied less 
often because they have very poor prognosis (lung and stomach) and are less likely to 
show any geographical differences in survival or results relating to them are difficult 
to interpret because of lead-time bias and length bias (prostate). Berrino et al41 
reported significant differences in relative survival for head and neck cancer patients 
diagnosed in 1985-89 between Eastern European countries and the rest of Europe, and 
the differences persisted after correcting for the distribution of cancer subsite. Using 
data from 45 European cancer registries, Post et al32 reported that 5-year relative 
survival from prostate cancer varied markedly from 40% to 72% among European 
countries. For lung cancer, the survival was very poor but age-standardised relative 
survival varied significantly within Europe, with 5-year relative survival for patients 
diagnosed in 1985-89 being between 5% and 12% for males and 7% and 18% for 
females.30 Similar results were also found in Denmark31 and England.29 Using Danish 
national cancer registry data, Madsen et al31 observed that survival from lung cancer 
was dependent on the place of residence and after adjusting for age and stage, 5-
month survival differed significantly between regions. Cartman et al29 also found 
significant variation in one-year survival from lung cancer between health authority 
districts in England and this variation remained after adjusting for age at diagnosis.  
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Studies comparing survival between geographical areas involving multiple cancer 
types were conducted in Australia,8 Canada,9 Italy,11 Nordic countries,22;23 Scotland7 
and the USA,10 and Europe,34;35;37;38 including cancers of the colon and rectum,7-
12;16;22;23
 breast,7-12;16;22;23 prostate,7-12;16;22;23 cervix,8;12;16;22 stomach,7;10;12;16;22;23 
ovary,7;10;12;16;22 and melanoma,8;12;16;22;23 and other cancer sites.8;10;12;16;22;23 In the 
report “Cancer survival in Australia 1992-1997”, men living in rural and remote areas 
were found to have poorer 5-year relative survival for all cancers, lung and prostate 
cancer and melanoma; women in those areas had poorer survival for lung and cervical 
cancers, compared with the metropolitan areas and large rural centres.8 Similarly in 
Scotland, Campbell et al7 found increasing distance from a cancer centre was 
associated with poorer survival and patients living in more remote areas were less 
likely to be diagnosed before they died, especially for stomach, breast and colorectal 
cancers. Part of the reason for this may be due to differences in stage at diagnosis 
between rural and urban areas, as increasing distance from a cancer centre was found 
to be associated with a high chance of disseminated disease at diagnosis (p=0.04).42 
 
In Canada, Ellison et al9 found that the survival rates of Canadians with cancer 
depended on in which region of the country they lived. They reported that on average, 
Canadian women with breast cancer have an 82 percent chance of surviving five years 
after diagnosis. This rose to 85 percent for women living in British Columbia, but 
dropped to 76 percent in Newfoundland and Labrador. The same pattern was repeated 
for men with prostate cancer.9  
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Gatta et al11 analysed population-based data on survival of cancer and compared 
survival between geographical areas in Italy. The data were from three cancer 
registries in Italy with 90,431 cases. They found that there were significant 
differences in survival between different areas of the country, particularly for cancers 
that respond well to treatment (eg. cancers of the breast, prostate and large bowel).11 
They thought that the unequal provision of care might explain the differences in 
survival between northern-central Italy and the south. Regional variation in cancer 
survival has been reported in the USA,10 including cancers of the stomach, colon, 
rectum, lung, breast, uterus, and prostate. Significant variation (p=0.01) in survival 
among SEER areas was observed for all individual cancers studied except for cancer 
of the ovary (p=0.04). After adjusting for stage, significant variation remained except 
for cancers of the ovary and bladder.10  
 
Intercountry differences in survival were also reported for many European countries, 
and between Europe and the USA. Using data from cancer registries in the Nordic 
countries, Engeland et al23 reported that Danish patients had a markedly lower relative 
survival than patients in other Nordic countries for cancers of the stomach, colon and 
rectum, breast and prostate. Sant et al16 calculated 5-year relative survival for 
1,836,287 patients diagnosed with one of 13 cancers between 1978 and 1989, using 
data from 20 cancer registries in 13 European countries. They found large disparities 
in survival between countries for most solid tumours (large bowel, breast, kidney, 
cervix, ovary, prostate and stomach, and melanoma of the skin). Generally survival 
was highest in Northern Europe and lowest in Eastern Europe, and was also low in the 
UK and Denmark. Less marked regional variation was found for the lymphomas and 
regional variation was not observed for cancers of the lung or brain.16 Analysing data 
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from 738,075 European and 282,398 US patients for each of the 12 major cancers 
diagnosed in 1985-1989, Gatta et al12 compared survival in Europe and the United 
States and found that Europeans had significantly lower survival than US patients for 
most cancers; greater differences were found for cancers of the prostate, colon, 
rectum, breast, uterus and melanoma. The survival differences were small for lung 
cancer and lymphomas, and no significant differences in survival were observed for 
stomach cancer.12 
   
 
Table 1. Summary of studies examining geographical variation in cancer survival 
First author (year) Cancer type(s) Population & setting Analysis Description of results 
Australian Institute of 
Health and Welfare 
(2003)8 
All cancers combined, 
colorectal, lung, melanoma, 
breast, cervix, prostate and 
NHL 
National cancer statistics 
clearing house data: 
Australia 
Relative survival Men living outside metropolitan areas and large rural centres had 
poorer 5-year survival for all cancers, lung and prostate cancer and 
melanoma; women in those areas had poorer survival for lung and 
cervical cancer 
Berrino (1998)41 Head and neck EUROCARE II Relative survival Significant differences in survival for head and neck cancer 
patients diagnosed in 1985-1989 were observed between Eastern 
countries and the rest of Europe and the differences persisted after 
correcting for differences in the distribution of sub-site  
Blomqvist (1997)43 Colon Swedish National Cancer 
Registry 
Relative survival 
for six 3-year 
periods from 
1973 to 1990 and 
multivariate 
analysis 
Relative survival from colon cancer improved substantially from 
1973 to 1990 and differences in survival between areas decreased 
during the study period; the authors think that the convergence of 
survival mainly can be attributed to improvements in care 
provided in the primary catchment areas of local and county 
hospitals 
Campbell (2000)7 Lung, colorectal, breast, 
prostate, stomach, ovary 
Scottish Cancer Registry 
data 
Cox regression Increasing distance from a cancer centre was associated with 
poorer survival for colorectal, breast and stomach cancers after 
adjusting for age, sex and settlement size 
Cartman (2002)29 Lung Northern and Yorkshire 
Cancer Registry data: UK 
Kaplan-Meier 
survival and Cox 
regression 
One-year survival varied significantly from 23% to 19% among 4 
groups of health authority districts and this difference was still 
present after adjusting for age at diagnosis 
Ciccolallo (2005)21 Colon and rectum 10 EUROCARE registries 
and 9 SEER registries in 
USA 
Relative survival 
modelling 
3-year relative survival was 69% for USA, 57% for European 
patients; after adjusting for age, sex and site, relative excess risk 
was significantly higher than the USA in all EUROCARE 
registries from 1.07 to 2.22 
Dickman (1997)22 12 common cancers National Cancer Registry 
data: Denmark, Finland, 
Norway, Sweden  
Relative survival 
modelling 
Significant regional variation in survival was found for 9 of the 12 
cancers studied, including cancers of the breast, lung, colon, 
rectum and prostate, and melanoma (detailed results for regional 
variation were presented for Sweden only) 
Eaker (2005)44 Breast  One clinical breast cancer 
register in Sweden 
Relative survival 
and Poisson 
regression 
7-year relative survival was lower in county A compared with 
several other counties; this difference decreased after adjusting for 
diagnostic activity and after county A began to strictly adhere to 
the regional breast cancer guidelines these differences disappeared 
1
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Ellison (2001)9 Breast, colorectal, lung and 
prostate 
Canadian Cancer Registry 
data 
Age-standardised 
relative survival 
Age-standardised relative survival differed significantly among 
provinces for prostate, breast and male lung cancer, but not for 
colorectal cancer 
   
 
First author (year) Cancer type(s) Population & setting Analysis Description of results 
Engeland (1998)23 Stomach, colon, rectum, 
breast, uterus, prostate, 
melanoma 
National Cancer Registry 
data: Denmark, Finland, 
Norway, Sweden, Iceland  
Relative survival Danish patients had a markedly lower relative survival than the 
patients in other Nordic countries for cancers of the stomach, 
colon, rectum, breast, and prostate 
Farrow (1996)10 Stomach, colon, rectum, 
lung, breast, uterus, ovary, 
prostate, bladder 
9 SEER registries USA Relative survival, 
Cox regression 
model 
Significant variation in survival among SEER areas was observed 
for all cancers studied (p<0.01), except ovary (p=0.04). After 
adjusting for stage, variation remained significant except for 
cancers of the ovary and bladder 
Gatta (1998)24 Colorectal cancer EUROCARE data from 
17 European countries 
Relative survival 5-year relative survival from colorectal cancer differed 
significantly across European countries, ranging from 23% to 59% 
for colon cancer and 22% to 53% for rectal cancer 
Gatta (2000a)25 Colorectal cancer 11 EUROCARE cancer 
registries  
3-year observed 
survival, Cox 
model 
3-year survival ranged from 25% to 59% across 11 population 
registries. After correction for stage, significantly different 
survival still existed between populations, with relative risk from 
0.76 to 1.81 
Gatta (2000b)12 12 major cancers 41 EUROCARE cancer 
registries and 9 SEER 
registries in USA 
Relative survival Europeans had significantly lower survival than US patients for 
most cancers; greater differences were for cancers of the prostate, 
colon, rectum, breast, uterus and melanoma 
Goodwin (2002)13 Breast SEER data: USA Kaplan-Meier 
survival 
Kaplan-Meier survival curves indicated significantly different 
survival among the 66 health service areas (p<0.0001) 
Janssen-Heijnen 
(1998)30 
Lung 44 EUROCARE cancer 
registries  
Age-standardised 
relative survival 
Age-standardised relative survival varied greatly within Europe, 
with 5-year relative survival from 5% to 12% in males and from 
7% to 18% in females 
Kim (2000)26 Colon and rectum South West Cancer 
Intelligence Unit: 
England 
Observed 
survival and Cox 
regression model 
Variation in survival from colorectal cancer across districts in 
southern England persisted after adjusting survival rates for age, 
stage and surgery type  
Madsen (2002)31  Lung National Cancer Registry 
data: Denmark 
Cox regression 
model 
Survival was dependent on place of residence. After adjusting for 
age & stage 5-month survival differed significantly between areas  
Mullee (2004)39 Breast National Cancer Registry 
data: England and Wales 
Relative survival, 
regression model 
Large and significant variation was found in 5-year relative 
survival (from 66% to 85%) among 99 health authorities 
(p<0.001) 
Post (1998)32 Prostate Data from 45 
EUROCARE registries  
Relative survival 5-year relative survival varied markedly from 40% to 72% among 
European countries 
1
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Prior (1998)27 Colon North Western Regional 
Cancer Registry: England 
Relative survival Relative survival for the North West cohort, based on the 
exclusion of cases with only a clinical diagnosis, was very close to 
that of the European cohort, suggesting the disadvantage in 
survival in the UK found in the EUROCARE study may be due to 
failure to record all advanced cases in some European registries  
   
 
First author (year) Cancer type(s) Population & setting Analysis Description of results 
Quinn (1998)14 Breast Data from 42 
EUROCARE registries  
Relative survival 5-year relative survival in 1985-1989 differed widely among 
countries, the lowest being 58% in Slovakia and highest being 
81% in Sweden 
Sant (1998)15 Breast Data from 25 
EUROCARE registries  
Relative survival  5-year relative survival varied from 61% to 78% across European 
countries 
Sant (2001)16 13 common cancers Data from 20 
EUROCARE registries  
Relative survival Survival was highest in Northern Europe and lowest in Eastern 
Europe, and also low in the UK and Denmark. The differences 
between 4 European regions decreased over time for cancers of the 
large bowel, breast, and melanoma and Hodgkin’s disease 
Sant (2003)17 Breast Data from 17 
EUROCARE registries 
Regression model 
for relative 
survival 
5-year relative survival varied significantly from 66% to 86% 
across 9 European countries. After adjusting for stage and number 
of lymph nodes examined, survival differences between countries 
were greatly reduced 
Sant (2004)18  Breast Data from SEER registry 
and 17 EUROCARE 
registries  
Regression model 
for relative 
survival 
5-year relative survival was 89% in USA and 79% in Europe. 
Significant difference was found after adjusting for age at 
diagnosis and surgery, but disappeared after full adjustment for 
stage 
Spilsbury (2005)19 Breast cancer patients with 
surgery 
Western Australia Cancer 
Registry data linked with 
hospital records 
Relative survival 
(RSR) and Cox 
regression 
Living in regional areas was associated with poorer survival 
(p<0.001), but residential location was not associated with survival 
after adjusting for treatment and health-related factors 
Twelves (2001)20 Breast Scottish Cancer Registry 
data 
Kaplan-Meier 
survival, Cox 
regression model 
Significant variation in the risk of death across health boards at 5 
years (p=0.04) and at 10 years (p=0.004) 
Verdecchia (2004)33 Gastric cancer Data from 47 
EUROCARE registries 
Regression model Significant differences in survival persisted among European 
countries after adjusting for age, subsite and histology 
1
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There tends to be greater geographical variation in survival when the comparison is 
between countries with large differences in political system and/or level of economic 
development (Table 2). For example, large and significant intercountry variation was 
found in the EUROCARE project for most cancers studied, with eastern European 
countries having lower survival generally compared with the average European 
rates.16 When comparing countries with similar political and economic development, 
the variation seems to be smaller. For example, for most cancers, the variation in 
survival between the Nordic countries was smaller than the differences found in the 
EUROCARE comparisons.23 Furthermore, variation in survival is less likely when the 
comparison is between areas in the same country. For example, the authors did not 
find significant geographical variation in colorectal cancer survival in either Australia 
or Canada,8;9 while wide and significant variation was found within Europe.16;24;25 On 
the other hand, as found in the EUROCARE studies,34 geographical variation in 
survival tends to be smaller16;25 or even disappears8 for lymphomas, probably because 
of the relative lack of available effective therapies, compared with many other 
cancers.  
 
For most cancers, survival differences between regions are probably due to variation 
in earliness of detection or diagnosis, or to regional differences in access to care and 
quality of care delivered. Numerous studies have provided scientific evidence of the 
relationships between treatment and outcomes, such as cancer specific survival or 
cancer recurrence. Supportive evidence for these explanations comes from recent 
detailed studies of breast and colorectal cancer, which showed strong evidence that 
the application of effective treatments reduced the differences in survival between 
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geographical areas (colon cancer in Sweden)43 and that regional differences in 
survival disappeared after adjusting for differences in treatment for breast cancer in 
Australia and Sweden.19;44 In a population-based study comparing survival differences 
in breast cancer between counties in different time periods in Sweden, Eaker and 
colleagues44 found that 7-year relative survival for breast cancer was significantly 
lower in one county in 1992-1993, but that this survival difference had disappeared in 
2000-2002 after this county began, in 1996-97, to adhere strictly to the regional breast 
cancer guidelines, including recruiting new staff members to the multidisciplinary 
breast team, active quality assurance of mammography screening and stricter 
adherence to guidelines for treating breast cancer patients. In an Australian study 
comparing survival after breast cancer surgery, Spilsbury et al19 found that women 
living in regional areas had poorer 5-year relative survival (p<0.001) than their 
counterparts in metropolitan areas, however, residential location was no longer 
associated with survival after adjusting for treatment, and health-related factors.  
   
 
Table 2. Summary of results of studies examining geographical variation in survival by cancer type 
Cancer type  First author (year) Extent of geographical variation in survival observed 
Australian Institute of Health and 
Welfare (2003)8 
Small but significant variation: 5-year relative survival (RSR): 79.9% in other rural areas (lowest) vs 82.8% national 
average 
Campbell (2000)7 Strong evidence of variation observed: after adjusting for age, sex and settlement size, increasing distance from a 
cancer centre was associated with poorer survival - odds ratio (OR) ranging from 1.0 in ≤5km to 2.9 ≥38 km (p for 
trend <0.001) 
Dickman (1997)22 Significant variation observed (p<0.01): with high number of deaths that could be prevented (284) (for Sweden only) 
Ellison (2001)9 Significant variation observed with 5-year RSR ranging from 76% (lowest) to 85% (highest) by province 
Engeland (1998)23 5-year RSR was markedly lower (69%) in Denmark than other Nordic countries (74% and 79% for Norway and 
Finland respectively)  
Farrow (1996)10 Significant regional variation observed: relative risk of deaths (RR) ranged from 0.77 to 1.19 across SEER areas 
(p<0.01)  
Gatta (2000b)12 Large differences in survival observed: Europeans had a higher (1.75) relative excess risk of death (RER) than 
people in the USA 
Goodwin (2002)13 Considerable variation was observed among 66 health service areas (p<0.0001) 
Mullee (2004)39 Large and significant variation observed: 5-year RSR ranged from 66% to 85% among 99 health authorities 
(p<0.001)  
Quinn (1998)14 Wide variation observed: 5-year RSR ranged from 56% to 83% across 13 European countries for patients diagnosed 
in 1987-89 
Sant (1998)15 Significant variation observed: 5-year RSR ranged from 61% to 78% across 11 European countries for women 
diagnosed in 1983-85 
Sant (2001)16 Wide and significant variation observed: 5-year RSR ranged from 55.8% in Eastern Europe to 80.5% in Northern 
Europe for patients diagnosed in 1987-89 
Sant (2003)17 Wide and significant variation observed: 5-year RSR varied from 66% to 85% across 9 European countries 
Sant (2004)18 Significant variation observed: 5-year RSR was 89% in the USA and 79% in Europe for women diagnosed in 1990-
92 
Spilsbury (2005)19 Significant variation observed: living in regional areas was associated with poorer survival (p<0.001) 
Breast 
Twelves (2001)20 Significant variation in the risk of death across health boards at 5 years (p=0.04) and at 10 years (p=0.004) 
Australian Institute of Health and 
Welfare (2003)8 
Variation was not significant between geographical areas for both sexes 
Campbell (2000)7 Evidence of variation observed: after adjusting for age, sex and settlement size, increasing distance from a cancer 
centre was associated with poorer survival - OR ranging from 1.0 in ≤5km to 1.8 ≥38 km (p for trend = 0.02) 
Ciccolallo (2005)21 Significant variation observed between Europe and the USA: 3-year RSR was 69% for USA and 57% for Europeans 
Dickman (1997)22 Significant variation observed (p<0.01): with high number of deaths that could be prevented (382) (for Sweden only) 
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Colon and 
rectum 
Ellison (2001)9 Little inter-provincial variation was observed for colorectal cancer 
   
 
Cancer type  First author (year) Extent of geographical variation in survival observed 
Engeland (1998)23 Denmark had lowest 5-year RSR among the Nordic countries since the mid 1970s  
Farrow (1996)10 Significant regional variation observed: RR ranged from 0.89 to 1.11 for colon cancer and 0.92 to 1.12 for rectal 
cancer across SEER areas (p<0.01)  
Gatta (1998)24 Large and significant variation observed within Europe: 5-year RSR ranged from 23% to 59% for colon cancer and 
22% to 53% for rectal cancer 
Gatta (2000a)25 Wide and significant variation observed within Europe: 3-year observed survival ranged from 25% to 59% across 11 
populations covered by registries  
Gatta (2000b)12 Large differences in survival observed: Europeans had a higher (1.5) RER than patients in the USA diagnosed in 
1985-89 
Kim (2000)26 Highly significant variation between districts observed: district of treatment was a significant determinant of survival 
(p<0.0001) 
Colon and 
rectum 
(continued) 
Sant (2001)16 Wide and significant variation observed: 5-year RSR ranged from 23% in Eastern Europe to 52% in Northern 
Europe for patients diagnosed in 1987-89 
Australian Institute of Health and 
Welfare (2003)8 
Significant variation in 5-year RSR observed: men living in small rural centres (8.0%) and other rural areas (8.5%) 
had significantly lower survival than the national average (10.5%) 
Campbell (2000)7 Evidence of variation observed: after adjusting for age, sex, deprivation and settlement size, increasing distance from 
a cancer centre was associated with poorer survival – hazard ratio (HR) ranged from 1.0 in ≤5km to 1.1 ≥38 km (p 
for trend = 0.02) 
Cartman (2002)29 Wide variation in survival observed: one-year survival was significantly better in the districts with highest rates of 
active treatment (23%) compared with 19% for those with lowest treatment rates 
Dickman (1997)22 Significant variation observed (p<0.01): with 249 deaths that  could be prevented (for Sweden only) 
Ellison (2001)9 Significant variation observed with 5-year RSR for men ranging from 8% (lowest) to 15% (highest) by province; for 
women the variation was not significant 
Farrow (1996)10 Significant regional variation observed: RR ranged from 0.95 to 1.11 for lung cancer across SEER areas (p<0.01)  
Gatta (2000b)12 Significant differences in survival observed: Europeans had a higher RER (1.2) than patients in the USA diagnosed 
in 1985-89 
Janssen-Heijnen (1998)30 Wide variation observed: 5-year RSR varied greatly within Europe from 5% to 12% in males and 7% to 18% in 
females 
Lung 
Madsen (2002)31  Significant variation observed: after adjusting for age and stage, 5-month survival varied significantly between 
regions 
Australian Institute of Health and 
Welfare (2003)8 
Significant variation observed: men living in ‘capital cities’ and ‘metropolitan areas’ had significantly better 
survival, and men in ‘rural and remote areas’ had significantly poorer survival compared with the national average 
Campbell (2000)7 Evidence of variation observed: after adjusting for age, sex, deprivation and settlement size, increasing distance from 
a cancer centre was associated with poorer survival – HR ranged from 1.0 in ≤5km to 1.2 ≥38 km (p for trend = 
0.04) 
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Prostate 
Dickman (1997)22 Large and significant variation observed (p<0.01): with 390 deaths that could be prevented (for Sweden only) 
   
 
Cancer type  First author (year) Extent of geographical variation in survival observed 
Ellison (2001)9 Large and significant variation observed with 5-year RSR for men ranging from 67% (lowest) to 91% (highest) by 
province 
Engeland (1998)23 Large and significant variation observed: with poorer 5-year RSR (41%) in Denmark compared with 56% in Norway 
and 59% in Finland 
Farrow (1996)10 Significant regional variation observed: RR ranged from 0.83 to 1.18 for prostate cancer across SEER areas (p<0.01)  
Gatta (2000b)12 Large and significant differences in survival observed: Europeans had a higher RER (2.8) than patients diagnosed in 
the USA in 1985-89 
Post (1998)32 Large and significant variation observed: 5-year RSR varied markedly from 40% to 72% among European countries 
Prostate 
(continued) 
Sant (2001)16 Wide and significant variation observed within Europe: 5-year observed survival ranged from 43% to 66% across 11 
populations covered by registries  
Australian Institute of Health and 
Welfare (2003)8 
Significant variation observed: men living in ‘other rural areas’ had poorer 5-year RSR than the national average, 
and variation was not significant for women 
Dickman (1997)22 Large and significant variation observed (p<0.01): with 408 deaths that could be prevented (for Sweden only) 
Engeland (1998)23 No marked differences were observed between the Nordic countries 
Gatta (2000b)12 Large and significant differences in survival observed: Europeans had a higher RER (1.8) than patients in the USA 
diagnosed in 1985-89 
Melanoma 
Sant (2001)16 Wide and significant variation observed within Europe: 5-year observed survival ranged from 62% to 88% across 11 
populations covered by registries  
Campbell (2000)7 Strong evidence of variation observed: after adjusting for age, sex and settlement size, increasing distance from a 
cancer centre was associated with poorer survival - OR ranging from 1.0 in ≤5km to 3.9 ≥38 km (p for trend <0.001) 
Dickman (1997)22 Small but significant variation observed (p<0.01): with 74 deaths that could be prevented (for Sweden only) 
Engeland (1998)23 Moderate variation observed: with poorer 5-year RSR (10%) for males in Denmark compared with 16% in Norway 
and 18% in Finland; 5-year RSR was similar for females 
Gatta (2000b)12 Little difference in survival observed: Europeans had a higher (21%) 5-year RSR than patients in the USA diagnosed 
(19%) in 1985-89 
Sant (2001)16 Wide and significant variation observed within Europe: 5-year observed survival ranged from 12% to 24% across 11 
populations covered by registries  
Stomach 
Verdecchia (2004)33 Significant variation observed: survival varied significantly across European countries after adjusting for age, 
subsite, histology and disease stage at diagnosis 
Australian Institute of Health and 
Welfare (2003)8 
No significant differences in 5-year RSR were observed across geographical areas 
Dickman (1997)22 No significant regional variation in 5-year RSR was observed (p=0.60) (for Sweden only) 
Gatta (2000b)12 Moderate but significant differences in survival observed: Europeans had a lower (61.8%) 5-year RSR than patients 
in the USA (66.1%) diagnosed in 1985-89 
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Cervix 
Sant (2001)16 Significant variation observed within Europe: 5-year observed survival ranged from 49% to 65% across 11 
populations covered by registries  
   
 
Cancer type  First author (year) Extent of geographical variation in survival observed 
Campbell (2000)7 No significant differences observed: distance from a cancer centre was not associated with survival (p for trend = 
0.26) 
Farrow (1996)10 No significant regional variation observed: RR ranged from 0.94 to 1.07 for ovarian cancer across SEER areas after 
adjusting for age (p>0.05)  
Gatta (2000b)12 Moderate but significant differences in survival observed: Europeans had a lower (32.9%) 5-year RSR than patients 
in the USA (39.5%) diagnosed in 1985-89 
Ovary 
Sant (2001)16 Significant variation observed within Europe: 5-year observed survival ranged from 26% to 42% across 11 
populations covered by registries  
Australian Institute of Health and 
Welfare (2003)8 
No significant differences in 5-year RSR were observed across geographical areas 
Gatta (2000b)12 Small but significant differences in survival observed: Europeans had a lower (46.7%) 5-year RSR than patients in 
the USA (50.3%) diagnosed in 1985-89 NHL 
Sant (2001)16 Regional variation was less marked for the lymphomas: 5-year observed survival ranged from 45% to 51% across 11 
populations covered by registries  
Gatta (2000b)12 Small but significant differences in survival observed: Europeans had a lower (71.7%) 5-year RSR than patients in 
the USA (74.9%) diagnosed in 1985-89 Hodgkin’s 
disease Sant (2001)16 Regional variation was less marked for the lymphomas: 5-year observed survival ranged from 66% to 72% across 11 
populations covered by registries  
2
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RSR – relative survival  RR – relative risk  RER – relative excess risk of death  HR – hazard ratio  NHL – non-Hodgkin lymphoma 
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Trends in survival over time 
Monitoring trends in patient survival is a useful approach for assessing performance in 
diagnosing and treating cancer patients over time. Cancer registries that record all new cases 
in a well-defined population represent the only way to assess real changes in the management 
of cancer at the population level. Patient survival rates provide useful information for doctors, 
patients and policy-makers, although estimates must be interpreted with care. The literature 
shows (Table 3) that survival from most cancers has improved since the 1980s in Canada,45 
England,46 Singapore,47 Sweden48 and the USA.49 EUROCARE is a large study designed to 
reliably compare population-based cancer survival across different countries in Europe. 
Comparing EUROCARE 2 and 3, the European average survival was found to have increased 
from the mid 1980s to 1992-94 for most major cancers.28 The increases in 5-year relative 
survival were marked for prostate cancer (55% to 68%), and substantial for breast cancer 
(70% to 77%), colorectal cancer (44% to 52%) and melanoma (68% to 78% for men and 82% 
to 88% for women), but only moderate for lung cancer (7.5% to 9.2% for men and 8.1% to 
9.8% for women).28 Across the Atlantic in the USA, improvement in 5-year relative survival 
was also seen for most cancers between 1975-79 and 1995-2000.49 The cancers with large 
gains in survival were cancers of the prostate, colon and rectum, breast and kidney, and NHL, 
while improvement was limited for cancers of the lung, pancreas, liver and oesophagus.49 
Similar results were also found in Canada,45 England,46 Singapore,47 Sweden48 and 
Switzerland.50 These studies did not, however, consider the effect of stage differences over 
time in their comparisons of survival over time. Therefore, there has been debate over the 
extent to which improved treatment has contributed to the trend in survival.51-53 
 
Although there are a variety of possible explanations for such an improvement, two of the 
most likely are earlier detection and improved treatment. Increasing survival over time may 
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reflect improvements in early detection by screening programs, improved treatment, or a 
combination of the two. Generally, one can separate the effect of earlier diagnosis from the 
effect of more effective treatment by comparing stage-specific survival or overall survival 
controlling for stage. If stage-specific survival stays the same over time, then better survival 
can be interpreted as a result of a more favourable stage distribution rather than more 
effective treatment.  
 
A few studies have taken account of changes in stage when assessing survival trends over 
time. A systematic analysis of patient survival over 40 years was conducted using Finnish 
Cancer Registry data.54 Also there have been studies of individual cancers of the breast55-
58and colon and rectum.59-62 All these studies found that increasing survival was partially 
independent of trends in stage over time. Thus authors interpreted the overall survival trends 
as being due to both earlier diagnosis and improvement in the management of cancer.  
 
There are some good examples of substantial improvements in survival that have probably 
been achieved by advances in treatment. In a study comparing survival from rectal cancer 
from 1960 to 1989 in Sweden, Dahlberg et al63 found that 5-year relative survival rates were 
very similar across regions in Sweden between 1960 and 1984; however significantly better 
survival was seen in one county compared to the rest of Sweden between 1985 and 1989. 
They believed that this improvement was a result of the introduction of combined 
preoperative radiotherapy and total mesorectal excision (TME) in 1985 in this county while 
not in the rest of Sweden.63 A more recent study supported this: as the improved surgical 
technique and preoperative radiotherapy was gradually adopted in the rest of Sweden since 
the early 1990s, the survival differences seen in 1985-89 disappeared.64 In an Australian 
study based on registry data linked with hospital records, authors observed a 15% increase in 
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relative survival from ovarian cancer between the periods of 1982-87 (38.8%) and 1994-98 
(53.5%), and they thought that the improved outcome was a result of a dramatic shift to the 
more aggressive, cytoreductive surgery in Western Australia over the past 20 years.65 In an 
English study, Reeves and colleagues66 studied survival trends from 1972 to 1984 in people 
aged less than 35 years diagnosed with leukaemia, Hodgkin’s disease, and testicular cancer 
using data from the National Cancer Registry in England. They found that 5-year relative 
survival for childhood leukaemia and testicular cancer improved dramatically from the mid 
1970s and to a lesser extent for Hodgkin’s disease. They argued that these improvements 
were mainly due to the introduction of new therapeutic modalities, cisplatin-based 
chemotherapy for testicular cancer and chemotherapeutic protocols together with increased 
centralisation of care for childhood leukaemia.66  
 
However, a few studies had reported that the improved survival in the most recent periods 
was due mainly to a more favourable stage distribution. Using data from a specialised 
colorectal cancer registry in Italy from 1984 to 1997, Ponz de Leon and colleagues67 found 
that 5-year relative survival was significantly more favourable in 1990-91 than it was in 
1984-89; but this upward trend was associated with a sharp increase in newly detected 
localised tumours in the more recent period. Thus, they concluded that the improved survival 
from colorectal cancer may be attributed to several concomitant factors, such as wider use of 
colonoscopy, increased education of patients and more attention given to symptoms.67 
Another study in Northern Ireland examined changes in survival from melanoma of the skin 
in two 5-year periods: 1984-88 and 1994-98.68 McMullen and co-workers found that patients 
diagnosed in the 2nd period had a one-third lower risk of dying than those in the 1st period. 
However, after adjustment for Breslow thickness and ulceration, the favourable survival in 
the 2nd period became non-significant (relative hazard=0.88, 95% confidence intervals (CI): 
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0.69-1.13). They concluded that the improved survival in the 2nd period was mainly due to 
detecting thinner melanoma and melanoma with less ulceration rather than advances in 
treatment.68  
 
 Table 3. Summary of studies examining trends in cancer survival over time 
First author (year) Cancer type(s) Population & setting Analysis Description of results 
Angell-Andersen 
(2004)59 
Colon and rectum National cancer registry: 
Norway 
Relative survival  50,993 cases diagnosed with colorectal cancer between 1958 and 
1997 were included in the analysis. 5-yr relative survival increased 
3% per 5-yr diagnostic period, from 40% in 1958-62 to 56% and 
60% in 1993-97 for males and females respectively.  
Birgisson (2005)64 Colon and rectum Swedish cancer registry RSR over 8 5-yr 
periods from 
1960 to 1999 
5-yr RSR improved significantly from 39.6% in 1960-64 to 57.2% 
in 1995-99 for colon cancer and from 36.1% to 57.6% for rectal 
cancer respectively; with the largest improvement of survival 
being in later periods studied  
Chia (2001)47 17 common cancers  National cancer registry: 
Singapore 
RSR over 5 5-yr 
periods from 
1968 to 1992 
Significant 5-yr RSR increases were seen for 9 cancers, including 
cancer of the colon-rectum, breast, cervix and NHL; no changes in 
survival over 25 years for cancers of the liver and pancreas 
Coleman (2004)46 20 common cancers National cancer registry: 
England 
RSR over 3 5-yr 
periods from 
1986 to 1999 
5-yr RSR increased for 11 of the 16 cancers for men, including 
colon, rectum, prostate and melanoma, not for cancers of the lung, 
pancreas and brain; for women 9 of the 17 cancers studied were 
increased significantly from 1986 to 1999 including breast, colon, 
rectum, ovary, but not for lung, pancreas, cervix and brain 
Dahlberg (1998)63 Rectum Swedish cancer registry RSR and 
multivariate 
analyses 
5-yr RSR were very similar across regions in Sweden between 
1960 and 1984; however, significantly better survival was seen in 
the county of Uppsala than in the rest of Sweden between 1985 
and 1989 as a result of the introduction of combined preoperative 
radiotherapy and total mesorectal excision (TME) in 1985 in 
Uppsala which was not widely performed in the rest of Sweden. 
Dickman (1999)54 Over 30 selected cancer 
types including colon, 
rectum, lung, breast, 
prostate and melanoma 
Finnish cancer registry Relative survival 
over four 10-year 
periods from 
1955 to 1994 
A gradual increase in 5-, and 10-yr relative survival from 1955-64 
to 1985-94 was observed for almost all individual cancers with the 
exception of cervical cancer. Compared with the 1975-84 period 
5-yr relative survival in 1985-94 improved for patients with major 
cancers, except for cancers of the pancreas, liver, lung & cervix 
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Du (2002)60 Colon and rectum National cancer registry: 
Singapore 
Stage-specific 
survival by 5 5-yr 
periods from 
1968 to 1992 and 
Cox regression 
5-yr RSR improved greatly over the study period for both colon 
and rectal cancer. After adjusting for age, sex, ethnic groups and 
clinical stage, period of diagnosis remained a significant factor for 
survival; the hazard ratio was 0.47 and 0.40 for the most recent 
period for colon and rectal cancer respectively 
   
 
First author (year) Cancer type(s) Population & setting Analysis Description of results 
Ellison (2004)45 Breast, lung, colorectal and 
prostate 
Canadian Cancer Registry Change in 5-year 
relative survival 
over time 
Between 1985-87 and 1992-94, increases in 5-year relative 
survival were dramatic for prostate cancer, large for breast cancer, 
and smaller for colorectal cancer, but little change for lung cancer  
Engel (2002)69 Ovary Munich cancer registry: 
Germany 
Kaplan-Meier 
(KM) survival 
curve  
Overall, the 5-year and 10 year stage-specific survival for those 
diagnosed in 1988-1997 improved only slightly compared with 
those diagnosed in 1978-1987  
Faivre-Finn (2002)61 Colon Cote-d’Or cancer registry: 
France 
Logistic 
regression  
Survival improved over the study period with 5-yr relative 
survival being 33.0% (1976-79), 40.9% (1980-83), 52.5% (1984-
87), 58.9% (1988-91) and 55.3% (1992-95), after adjusting for 
age, stage, subsite and emergency surgery or not, period of 
diagnosis was strongly related to survival (p<0.0001)  
Jensena (2003)55 Breast National cancer registry: 
Denmark 
Kaplan-Meier 
survival curves 
An overall improvement in survival was seen in two of the 3 
counties studied with the 3rd one experiencing no change in 
survival.  
Laurivick (2003)65 Ovary Western Australian 
cancer registry linked 
with hospital records 
Relative survival 
and logistic 
regression 
A 15% increase in relative survival was observed between 1982-
87 (38.8%) and 1994-98 (53.5%) with a significant increase in 
surgical procedures over the same period 
Levi (2000)50 29 common cancers and all 
cancers combined 
Vaud cancer registry: 
Switzerland 
RSR over 4 
periods of 
diagnosis 
5-yr RSR for all cancers increased from 51% in 1974-78 to 64% in 
1989-93; most cancer sites showed an increase in 5-yr RSR, 
including colon, rectum, lung, breast, prostate and melanoma 
Martijn (2003)62 Rectum (diagnosed from 
1980 to 2000) 
Eindhoven cancer 
registry: the Netherlands 
Relative survival 
and Cox 
regression for 3 
periods  
5-yr relative survival increased from 49% in 1980-89 to 55% in 
1990-94, and 61% in 1995-2000; after adjusting for age, gender, 
subsite and stage, significant improvements in the overall 
prognosis were found for patients aged less than 60 years and 
those 60-74 years old, but not for those aged 75 or over 
McMullen (2004)68 Melanoma Northern Ireland cancer 
registry 
KM survival 
curves and Cox 
regression 
5-yr survival increased from 71.0% in 1984-88 to 77.4% in 1994-
98; after allowing for age and sex, patients diagnosed in the 2nd 
period had a 30% lower risk of dying than those diagnosed in the 
1st period (RH=0.71). However, after additional adjustment for 
Breslow depth and ulceration, the favorable survival in the recent 
period became non-significant (RH=0.88 95% CI: 0.69-1.13) 
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Ponz de Leon (2000)67 Colon and rectum Modena colorectal cancer 
registry: Italy 
KM survival 
curves  
Survival was significantly higher in patients diagnosed in 1990-91 
for both colon (p=0.004) and rectal cancer (p=0.02) than in 1984-
89 
   
 
 
 
First author 
(year) 
Cancer type(s) Population & 
setting 
Analysis Description of results 
Reeves (1999)66 Breast, testicular 
cancer, Hodgkin’s 
disease, acute 
lymphatic leukaemia, 
acute myeloid 
leukaemia 
National cancer 
registry data: England 
(only a subset of those 
15-34 years old but for 
leukemia those aged 0-
14 years also included) 
Change in 
relative survival 
over 4 periods 
between 1972 
and 1984 
5-year RSR for childhood leukaemia improved from 9% in 1972-75 to 34% in 
1982-84 for AML, whereas for ALL it increased from 45% to 75% over the same 
period; for those aged 15-34 years, 5-year RSR for AML increased from 6% in 
1972-75 to 31% in 1982-84, figures for ALL showed an increase from 22% to 44% 
over the same period; 5-year RSR for testicular cancer also showed a gradual and 
significant increase; while the increase for Hodgkin’s disease was moderate. There 
was little change for breast cancer 
Sant (2003)28 12 groups of common 
cancers 
EUROCARE-3 data RSR comparison 
between 1983-85 
and 1992-94 
Overall European 5-yr RSR increased from 1983-85 to 1992-94 for the major 
cancers: lung (7.5% - 9.2% for men; 8.1% - 9.8% for women), colorectum (44% - 
52%), melanoma (68% - 78%), breast (70% - 77%), prostate (55% - 68%) 
Spilsbury 
(2005)19 
Breast cancer patients 
with surgery 
Western Australian 
cancer registry data 
linked with hospital 
records 
RSR over 4 4-yr 
periods from 
1982 to 1997 
5-yr RSR from breast cancer after surgery increased significantly (p<0.001) from 
77% in 1982-85 to 86% in 1994-97. After adjusting for age, hospital type, 
comorbidity and treatment type, period of diagnosis remained significant 
Talback (2003)48 All cancers combined, 
oesophagus, colon, 
rectum, lung, breast, 
cervix, uterus, ovary, 
prostate, melanoma etc 
40 cancer types  
Swedish cancer registry 5, 10, 15, 20 year 
relative survival 
from 1960 to 
1998 
This study included 1,021,421 patients diagnosed with one of the 40 cancers in 
Sweden in 1960-1998. During the 1990s substantial survival improvements were 
observed not only for uncommon cancers, such as testicular cancer, Hodgkin’s 
lymphoma, but also for cancer of the rectum, kidney and melanoma. Survival for 
breast and cervical cancer also improved during the 1990’s, but not for pancreatic, 
liver and lung cancers 
Taylor (2003)56 Breast NSW state cancer 
registry: Australia 
RSR over 5 5-yr 
periods  
5-yr RSR improved over the 5 periods of diagnosis from 1972 to 1996, especially 
from the late 1980s onwards 
Thomson 
(2004)57 
Breast: diagnosed in 
1987 and 1993 
Scottish cancer registry Kaplan-Meier 
survival curve 
and Cox 
regression for 
both cohorts 
Significant improvements in survival was seen for those diagnosed in 1993, after 
adjustment for all the clinical/pathological factors the risk of death was still lower 
in 1993 (p=0.03); with additional adjustment for all healthcare delivery the cohort 
effect remained significant (p=0.03); screening appeared to make the biggest 
contribution among all the healthcare & demographic factors 
Webb (2004)58 Breast Case-control study: 
Queensland, Australia 
Relative survival 5-yr RSR was better among women diagnosed in 1990-94 (84%) than those 
diagnosed in 1981-84 (74%), after adjusting for tumour size and nodal status, this 
difference reduced but still persisted 
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Methodological issues for interpreting temporal or geographical variation 
Temporal and geographical variation in survival can be due to several factors, including the 
quality of treatment received. It may also be due to other factors, such as variation in the 
extent of disease at diagnosis and in the histology and grade of tumours, or artefacts in the 
data, such as stage migration. Therefore, interpretation of comparative survival, either time 
trends or geographical differences based on population-based cancer registry data, is generally 
not easy. For example, temporal or geographical differences in cancer survival could be 
attributed to a number of real factors, including access to primary health care, the availability 
of diagnostic and treatment facilities and the treatment actually given, or it might simply be 
due to statistical artefacts (lead-time bias, confounding factors, stage migration, sampling 
error or measurement error). Alternatively a combination of several of these factors may 
produce both real and artefactual differences. 
 
Lead-time and length bias 
If a cancer is detected by screening, the survival time is increased by an amount known as 
lead time,70 without necessarily postponing the time of death. For example, in a comparison of 
survival between Europe and the USA using EUROCARE and SEER registry data, Gatta et 
al12 found that higher survival in the USA patients for breast, colon and rectum, and prostate 
cancers coincided with a higher incidence of these cancers, thus they thought this was likely 
due to the inclusion of more early stage small tumours identified by screening in the USA 
cohort.  
 
Length-bias occurs when slow-growing, less aggressive cancers with good prognosis are 
preferentially detected by screening. An extreme form of length-bias is overdiagnosis; that is 
the detection of tumours that would never have caused harm to the patient if they had not been 
screen-detected. The large uptake of prostate-specific antigen (PSA) testing, starting around 
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1990, in the USA led to escalating incidence of prostate cancer71 and corresponding survival 
increases. This coincidence suggests that the apparent increase in survival since the early 
1990s was mainly due to length bias (and probably some lead-time bias), because the patients 
diagnosed with PSA are substantially ‘diluted’ with many nonfatal cases. The same was found 
in Europe when studying survival trends for prostate cancer.28;72 Thus, differences in 
screening rates across geographical areas or over time could affect comparisons of survival 
rates between regions or time trends. 
 
Stage-adjusted or stage-specific estimates of survival may be helpful in understanding 
temporal trends in survival, but they should be interpreted with caution. Because some 
cancers, such as breast, colorectal and prostate, are commonly diagnosed through screening 
programs, survival for these cancers is susceptible to the effects of lead-time bias and length 
bias. These effects may lengthen apparent survival time without providing benefit to the 
patient. Theoretically, stage adjustment should reduce the magnitude of lead-time bias but 
does not eliminate it because there is a within stage shift.73 Such adjustment, however, has 
little or no effect on length bias73 because through screening, a totally new class of cancers is 
diagnosed with a different behaviour (ie no capacity to kill) than tumours detected otherwise 
in the same stage categories.  
 
Stage migration 
Stage migration74 can bias geographical or temporal comparisons of survival. In studies of 
trends in survival, it can produce an apparent improvement in stage-specific or stage-adjusted 
survival as a result of the introduction of more sensitive staging tools. That is, patients with 
otherwise clinically silent metastatic lesions are reclassified to more advanced stages because 
these tools find at least some of these silent metastases. This shift from earlier to more 
advanced stages appears to improve survival in both earlier and advanced stages but results in 
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no overall improvement for the entire cohort. For example, in a German study examining 
trends in survival for ovarian cancer from 1978 to 1997, Engel et al69 found that survival 
improved about 10% for early stages but survival for the total sample hardly changed. They 
thought that stage migration may have contributed to the apparent improvements in survival 
from early stage tumours since classification was more accurate in the recent period.69  
 
By the same token, in studies of geographical differences in survival, stage migration might 
affect the comparability of stage-specific or stage-adjusted survival estimates because tumours 
classified as “localized” in one area are possibly “more localized” than tumours assigned the 
same stage in other areas. In a study aimed at improving the interpretation of survival 
differences between Europe and US women with breast cancer, Sant and colleagues18 used 
multiple regression models to assess the impact of stage and staging procedure on survival 
estimates for women diagnosed in 1990-92. They found that the differences in relative excess 
risk gradually reduced from model 1, only adjusting for age at diagnosis, model 2 with 
additional adjustment for surgery, to model 3 with further adjustment for stage at diagnosis, 
but the difference was still significant (RER for EUROCARE = 1.12, 95% CI: 1.03-1.22). 
They used the adjustment for number of lymph nodes examined pathologically to partially 
address the problem of stage migration, and found that after this adjustment in the final model 
the differences in RER reduced further (RER for EUROCARE=1.07, 95% CI: 0.98-1.17) and 
became not statistically significant.18 Thus, stage migration must be considered in interpreting 
survival differences temporally or geographically. 
 
Sampling error 
When survival rates are calculated for areas with small populations, the estimates can be 
affected by sampling error, reducing the precision of estimates for individual areas. Sampling 
error observed in areas with small populations can also mask true regional variation in cancer 
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survival. For example, in a study of fire and burn-related mortality rates by counties in the 
USA, 77 (25%) counties with high rates had five or fewer observed deaths over the entire 9 
year study period and the authors believed that the high rates in many of these counties were 
likely due to sampling error rather than true elevation in underlying risk.75 Similarly when 
comparing survival for non-common cancers the number of cases would be small in sparsely 
populated areas, and addition or omission of one or two cases would cause drastic changes in 
their estimates. Consequently, use of such estimates can introduce errors in decision-making 
for health service planning. 
 
Measurement error 
Disease stage at diagnosis is considered the most important prognostic factor in most cancers. 
Therefore, any comparison of outcome between populations or at different times must be 
adjusted for stage. To disentangle the effect of early diagnosis with the effect of treatment in 
explaining geographical or temporal differences in survival, it is essential to have reliable data 
on cancer stage. Measurement error in stage would be expected to reduce our ability to control 
for the effects of earlier detection and thus, may lead to incorrect inferences about the effects 
of treatment. In a recent study examining variability in axillary lymph nodes dissection for 
breast cancer among 19 hospitals in the Netherlands, Schaapveld et al76 found that a more 
extensive surgical dissection or pathological examination of the specimen resulted in a higher 
number of positive nodes, and false negative axillary staging, due to low level axillary 
dissection or lymph nodes examined in some hospitals, would influence the risk of recurrence 
and hence survival of individual breast cancer patients.77  
 
Other kinds of measurement error may also be important in some cancer registries. They may 
include, incomplete ascertainment of incident cases with, for example, a bias towards 
ascertainment of more advanced disease (if, for example, many cancers are first detected from 
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death notifications);40 inaccurate diagnosis of the type of cancer;27 and failure to ascertain all 
deaths that have occurred in the cohort of cancer patients78 (eg, through passive follow-up by 
linkage to death registries, which will miss deaths in people who have migrated from the area 
covered by the deaths data base and deaths that fail to link because of incompleteness or error 
in the identifiers in either database). In a more recent study assessing the impact on survival 
estimates of incomplete ascertainment of cancer cases and cases identified through death 
certificate only (DCO), Robinson et al79 found that there were large effects of incompleteness 
and DCO cases on estimated survival figures. They recommended that future studies should 
take variation in the proportion of DCO and completeness into consideration when comparing 
survival between different populations.79 
 
In summary, this literature review demonstrated that survival analysis using population-based 
cancer registry data can be used in monitoring and evaluating the diagnosis and treatment of 
cancer at the population level. There was wide variation in survival from many cancers among 
European countries, SEER areas in the USA, and areas in Canada and Australia. Patient 
survival has improved since the 1980s for most cancers in most countries included in this 
review. However, there are many limitations of such studies and researchers using such data 
should be aware of them when assessing them, analysing the data and interpreting the results. 
 
